β2 microglobulin as a surrogate marker for HIV infection: Good correlation with CD4 counts

Indian Journal of Pathology and Microbiology

Volumn 47, Issue 2, 2004, Pages 298-301

  Wanchu, A ^a   Arora, S ^a   Bhatnagar, A ^a   Sud, A ^a   Bambery, P ^a   Singh, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

2microglobulin; CD4 counts; Disease progression; HIV infection

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; OPPORTUNISTIC INFECTION; BLOOD; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; IMMUNOLOGY; INDIA; MIDDLE AGED;

ADULT; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INDIA; MALE; MIDDLE AGED;

EID: 27844565802     PISSN: 03774929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Fauci AS, Macher AM, Longo DL et al. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic and therapeutic consideration. Ann Int Med 1984; 100:92-106.
2. Fahey JL, Prince H, Weaver M et al. Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immunodeficiency syndrome from other immune subset disorders. Am J Med 1984; 76:95-100.
3. Polk BF, Fox R, Brookmayer R et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987; 316:61-6.
4. Goedert JJ, Biggar RJ, Weiss SH et al. Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science 1986; 231:992-5.
5. Detels R, Visscher BR, Fahey JL et al. Predictors of clinical AIDS in young homosexual men in a high-risk area. Int J Epidemol 1987; 16:271-6.
6. Fahey JL, Taylor JMG, Detels R et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type I. N Engl J Med 1990; 322:166-72.
7. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich P, Watcher H. Neopterin as a marker for activated cell-mediated immunity. Immunol Today 1988; 9:150-5.
8. Kovacs JA, Baselier M, Dewar RJ et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immuno-deficiency virus infection. New Engl J Med 1995; 332:567-75.
9. Fahey JL, Taylor JMG, Detels R et al. The prognostic value of cellular and serological markers in infection with human immunodeficiency virus type I. New Engl J Med 1990; 322:166-72.
10. Martinez-Bru C, Cortes M, Planella T et al. Beta 2-microglobulin and immunoglobulins are more useful markers of disease progression in HIV than neopterin and adenosine deaminase. Ann Clin Biochem 1999; 36:601-8.
11. Aziz N, Nishanian P, Fahey JL. Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures. Clin Diag Lab Immunol 1998; 5:755-61.
12. Planella T, Cortes M, Martinez-Bru C, Barrio J, Sambeat MA, Gonzalez-Sastre F. The predictive value of several markers in the progression to acquired immunodeficiency syndrome. Clin Chem Lab Med 1998; 36:169-73.
13. Mocroft A, Johnson MA, Sabin CA, Bofill M, Janossy G, Phillips AN. The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. Epidemiol Infect 1997; 118:259-66.
14. Phillips AN, Sabin CA, Elford J et al. Serum beta 2-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of followup. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:262-6.
15. Concorde Coordinating Committee. Concorde MRC/ANRS randomised double blind controlled trial of intermediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343:871-81.
16. Machado SG, Gau MH, Ellenberg SS. On the use of laboratory markers as surrogates for the clinical endpoints in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr 1990; 3:1065-73.
17. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell change, and development of AIDS. J Acqir Immune Defic Syndr 1989; 2:70-6.
18. Romanagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991; 12:256-7.
19. Michel P, Balde AT, Roussilhon C, Aribot G, Sarthou JL, Gougeon ML. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J Infect Dis 2000; 18:64-75.
20. Perez de Oteyza C, Menendez Martinez MA, Muro Garcia R, Perez Aznar Barberan Lopez J. Discriminative value for AIDS case of erythrocyte sedimentation rate, immunoglobulins IgA and IgM, and beta 2-microglobulin in combination with the CD4+ lymphocyte count. An Med Interna 1998; 15:411-4.
21. Wanchu A, Arora S, Bhatnagar A, Sud A, Bambery P, Singh S. Suppression of Beta-2 Microglobulin by Pentoxiphylline therapy in asymptomatic HIV infected individuals. Indian J Med Res 2001; 113:75-7.
22. Halota W, Jaruga B, Pawlowska M. Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS. Pol Merkuriusz Lek 2002; 13:126-8.
23. D E Nilssen, O Øktedalen, P Brandtzaeg. Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy. Gut 2004; 53:487-93.